Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Floyd, E.
Right arrow Articles by Mcshane, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Floyd, E.
Right arrow Articles by Mcshane, T. M.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cancer
*Cancer Chemotherapy
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Development and Use of Biomarkers in Oncology Drug Development

Eugenia Floyd

Pfizer Inc., PGRD Groton Laboratories, Eastern Point Road, Groton, Connecticut, USA, eugeniafloyd{at}groton.pfizer.com

Teresa M. Mcshane

Pfizer Inc., PGRD Groton Laboratories, Eastern Point Road, Groton, Connecticut, USA

Successful development and use of biomarkers will improve the productivity of oncology drug development. Recognition of the importance of biomarkers for speeding drug development is reflected in the precise definitions and concepts proposed by an NIH Working Group to standardize terminology and promote a more coherent and systematic approach to the development and use of biomarkers. Potential clinical biomarkers of drug efficacy are often identified through pre-clinical studies or basic research. Identification of potential biomarkers for use in oncology is moving rapidly forward through continuing advances in clinical imaging technologies, especially molecular and functional imaging. Other rapid advances are a product of the growing availability of new scientific reagents for established technologies and of high-throughput genomic and proteomic technologies that can generate hundreds of potential biomarkers for further evaluation. In certain cases, conventional clinical diagnostic techniques or assays can be adapted for use in pre-clinical models to evaluate their ability to serve as biomarkers for predicting clinical responses to new drug candidates. Evaluation (pre-clinical and clinical) of a potential biomarker is often the longest stage of biomarker development, and standards for evaluation or validation depend on the intended use and stage of clinical development. Biomarkers verified for use in preclinical studies can be used to help select appropriate animal models and lead compounds. Biomarkers verified for use in clinical trials can confirm a drug's pharmacological or biological mechanism of action, guide protocol design, aid patient and dose selection, and help to minimize safety risks. Oncology drug development can be optimized by using a tiered set of clinical biomarkers that predict compound efficacy and safety with increasing confidence at each rise in tier thereby aiding corporate decision-making about advancing compounds. In oncology, a special class of extensively evaluated biomarkers of efficacy (surrogate endpoints) that generally correlate with desired clinical outcomes can be used as a basis for corporate decisions as well as for gaining accelerated provisional regulatory approval of a drug.

Key Words: Cancer • anti-cancer drug • surrogate endpoint • molecular imaging • MRI • PET • immunohistochemistry • genomics • proteomics.

References

  • Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I., and Baselga, J. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1), 110—24.[Abstract/Free Full Text]
  • Allen, L.F., Lenehan, P.F., Eiseman, I.A., Elliott, W.L., and Fry, D.W. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29 (3 Suppl 11), 11— 21.[Web of Science][Medline] [Order article via Infotrieve]
  • Ardekani, A.M., Petricoin, E.F., and Hackett, J.L. (2003). Molecular diagnostics: an FDA perspective. Expert Rev Mol Diagn 32(2), 129—40.
  • Arteaga, C.L. (2003). Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 5(2), 96—100.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Baak, J.P.A. (2002). The framework of pathology: Good Laboratory Practice by quantitative and molecular methods. J Pathol 198, 277—83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barker, P.E. (2003). Cancer biomarker validation: standards and process. Roles for the National Institute of Standards and Technology (NIST). Ann NY Acad Sci 983, 142—50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bernard, P.S., and Wittwer, C.T. (2002). Real-time PCR technology for cancer diagnostics. Clin Chem 48(8), 1178—85.[Abstract/Free Full Text]
  • Beshara, N., Fung, M.F.K., and Faught, W. (2002). The role of topotecan as a second-line therapy in patients with recurrent ovarian cancer. Eur J Gynaecol Oncol 23, 287—90.[Web of Science][Medline] [Order article via Infotrieve]
  • Betensky, R.A., Louis, D.N., and Cairncross, J.G. (2002). Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20(10), 2495—9.[Abstract/Free Full Text]
  • Biomarkers Defininitions Working Group (2001 ). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharma col Ther 69, 89—95.
  • Blasberg, R. (2003). Molecular imaging and cancer. Mol Cancer Ther 2, 333—43.[Free Full Text]
  • Brodie, A. (2003). Aromatose inhibitor development and hormone therapy: a perspective. Semin Oncol 30, 12—22.[Web of Science][Medline] [Order article via Infotrieve]
  • Bruzzi, P. (2002). Objective response to treatment as a potential surrogate marker of survival in breast cancer. Ann NY Acad Sci 963, 144—7.[Web of Science][Medline] [Order article via Infotrieve]
  • Butte, A. (2002). The use and analysis of microarray data. Nature Rev Drug Disc 1(12), 951—60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Camp, R.L., Chung, G.G., and Rimm, D.L. (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med 8(11), 1323—7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002). Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev Drug Discov 1(7), 493—502.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chaurand, P., Schwartz, S.A., and Caprioli, R. (2002). Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr Opin Chem Biol 6(5), 676—81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Choyke, P.E., Dwyer, A.J., and Knopp, M.V. (2003). Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Res Imaging 17, 509—20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Colburn, W.A. (2003). Biomarkers in drug discovery and development: From target identification through drug marketing. J Clin Pharmacol 43(4), 329— 41.[Abstract/Free Full Text]
  • Dancey, J., and Sausville, E.A. (2003). Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev Drug Disc 2, 296—313.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Gruttola, V.G., Clax, P., DeMets, D.L., Downing, G.J., Ellenberg, S.S., Friedman, L., Gail, M.H., Prentice, R., Wittes, J., and Zeger, S.L. (2001). Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop. Control Clin Trials 22(5), 485—502.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Deptala, A., Bedner, E., and Darzynkiewicz, Z. (2001). Unique analytical capabilities of laser scanning cytometry that complement flow cytometry. Folia Histochem Cytobiol 39, 87—9.[Medline] [Order article via Infotrieve]
  • DePrimo, S.E., Wong, L.M., Khatry, D.B., Nicholas, S.L., Manning, W.C., Smolich, B.D., O'Farrell, A.M., and Cherrington, J.M. (2003). Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 3, 3.[Medline] [Order article via Infotrieve]
  • DiMasi, J.A. (2002). The value of improving the productivity of the drug development process. Pharmacoeconomics 20 (Suppl. 3), 1—10.[Web of Science][Medline] [Order article via Infotrieve]
  • DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22(2), 151—85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Duffy, M.J. (2001). Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38(3), 225—62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Early Detection Research Network (2002). Translational research to identify early cancer and cancer risk, second report. <http://www.3.cancer.gov/prevention/cbrg/edrn/publications.html >.
  • Eckelman, W.C. (2003). The use of PET and knockout mice in the drug discovery process. Drug Discov Today 8(9), 404—10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fauntleroy, M. (2001). Submission of images to the Center for Biologics Evaluation and Research in support of license applications for therapeutic agents. J Clin Pharmacol 41 (Suppl. S), 119S—21S.[CrossRef]
  • Frank, R., and Hargreaves, R. (2003). Clinical biomarkers in drug discovery and development. Nature Rev Drug Discov 2(7), 566—80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haedicke, W., Popper, H.H., Buck, C.R., and Zatloukal, K. (2003). Automated evaluation and normalization of immunohistochemistry on tissue microarrays with a DNA microarray scanner. Biotechniques 35, 164—8.[Web of Science][Medline] [Order article via Infotrieve]
  • Han, M., Gao, X., Su, J.Z., and Nie, S. (2001). Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nature Biotechnol 19, 631—5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hariharan, R. (2003). The analysis of microarray data. Pharmacogenomics 4, 477—97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hirschfeld, S., and Pazdur, R. (2002). Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42(2), 137—43.[Web of Science][Medline] [Order article via Infotrieve]
  • Howell, K., Hopkins, N., and Mcloughlin, P. (2002). Combined confocal microscopy and stereology: a highly efficient and unbiased approach to quantitative structural measurement in tissues. Exp Physiol 87(6), 747— 56.[Abstract]
  • Howells, S.L., Maxwell, R.J., and Griffiths, J.R. (1992). Classification of tumor 1 H NMR spectra by pattern recognition. NMR Biomed 5, 59—64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Howells, S.L., Maxwell, R.J., Howe, F.A., Peet, A.C., Stubbs, M., Rodrigues, L.M., Robinson, S.P., Baluch, S., and Griffiths, J.R. (1993). Pattern recognition of 31P magnetic resonance spectroscopy tumour spectra obtained in vivo. NMR Biomed 6, 237—41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R.G., West, M., and Nevins, J.R. (2003). Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genet 34, 226—30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hutchinson, O.C., Collingridge, D.R., Barthel, H., Price, P.M., and Aboagye, E.O. (2003). Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. J Curr Pharm Des 9, 917—29.[CrossRef]
  • Hutchinson, O.C., Collingridge, D.R., Barthel, H., Price, P.M., and Aboagye, E.O. (2003). Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. J Curr Pharm Des 9, 931—44.[CrossRef]
  • Jackson, J.K., Gleave, M.E., Yago, V., Beraldi, E., Hunter, W.L., and Burt, H.M. (2000). The suppression of human prostate tumor growth in mice by the injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res 60(15), 4146—51.[Abstract/Free Full Text]
  • Johnson, J.R., Williams, G., and Pazdur, R. (2003). End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21, 1404—11.[Abstract/Free Full Text]
  • Jubb, A.M., Landon, T.H., Burwick, J., Pham, T.Q., Frantz, G.D., Cairns, B., Quirke, P., Peale, F.V., and Hillan, K.J. (2003). Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol 200(5), 577—88.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kamentsky, L.A., Burger, D.E., Gershman, R.J., Kamentsky, L.D., and Luther, E. (1997). Slide-based laser scanning cytometry. Acta Cytol 41, 123— 43.[Web of Science][Medline] [Order article via Infotrieve]
  • Kavanaugh, C.J., Desai, K.V., Calvo, A., Brown, P.H., Couldrey, C., Lubet, R., and Green, J.E. (2002). Preclinical applications of transgenic mouse mammary cancer models. Transgenic Res 11, 617—33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kellar, K.L., and Iannone, M.A. (2002). Multiplexed microsphere-based flow cytometric assays. Expl Hematol 30(11), 1227—37.[CrossRef]
  • Kennedy, T. (1997). Managing the drug discovery/development interface. Drug Discov Today 2(10), 436—44.[CrossRef][Web of Science]
  • Keyes, K.A., Mann, L., Cox, K., Treadway, P., Iversen, P., Chen, Y.F., and Teicher, B.A. (2003). Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 51(4), 321—7.[Web of Science][Medline] [Order article via Infotrieve]
  • Korn, E.L., Arbuck, S.G., Pluda, J.M., Simon, R., Kaplan, R.S., and Christian, M.C. (2001). Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19(1), 265—72.[Abstract/Free Full Text]
  • Lee, K.E., Sha, N., Dougherty, E.R., Vannucci, M., and Mallick, B.K. (2003). Gene selection: a Bayesian variable selection approach. Bioinformatics 19, 90—7.[Abstract/Free Full Text]
  • Lesko, L.J., and Atkinson, A.J. (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41, 347—66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lim, Y.T., Kim, S., Nakayama, A., Stott, N.E., Bawendi, M.G., and Grangioni, J.V. (2003). Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging 2, 50—64.[CrossRef][Medline] [Order article via Infotrieve]
  • Liotta, L.A., Espina, V., Mehta, A.I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P.J., Young, L., Wulfkuhle, J., and Petricoin E.F. (2003). Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3(4), 317—25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lopez, A.M., Pegram, M.D., Slamon, D.J., and Landaw, E.M. (1999). A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci 96, 13023—8.[Abstract/Free Full Text]
  • Ma, P.C., Blaszkowsky, L., Bharti, A., Ladanyi, A., Kraeft, S.K., Bruno, A., Skarin A.T., Chen, L.B., and Salgia, R. (2003). Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 23(1A), 49—62.[Web of Science][Medline] [Order article via Infotrieve]
  • MacGregor, P.F., and Squire, J.A. (2002). Application of microarrays to the analysis of gene expression in cancer. Clin Chem 48(8), 1170—7.[Abstract/Free Full Text]
  • Malik, S.N., Siu, L.L., Rowinsky, E.K., deGraffenried, L., Hammond, L.A., Rizzo, J., Bacus, S., Brattain, M.G., Kreisberg, J.I., and Hidalgo, M. (2003). Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9, 2478—86.[Abstract/Free Full Text]
  • Mancuso, P., Calleri, A., Cassi, C., Gobbi, A., Capillo, M., Pruneri, G., Martinelli, G., and Bertolini, F. (2003). Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 522, 83—97.[Web of Science][Medline] [Order article via Infotrieve]
  • Mandell, J.W. (2003). Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 163, 1687—98.[Abstract/Free Full Text]
  • Mannix, D.G. (2000). Irinotecan—a case study for the transition from accelerated approval to traditional approval. Drug Inform J 34, 737—40.[Web of Science]
  • Massoud, T.F., and Gamghir, S.S. (2003). Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17, 545—80.[Free Full Text]
  • Mauro, M.J., O'Dwyer, M., Heinrich, M.C., and Druker, B.J. (2002). STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 20, 325—34.[Abstract/Free Full Text]
  • McCaffrey, A., Kay, M.A., and Contag, C.H. (2003). Advancing molecular therapies through in vivo bioluminescent imaging. Mol Imaging 2, 75— 86.[CrossRef][Medline] [Order article via Infotrieve]
  • McDonald, D.M., and Choyke, P.L. (2003). Imaging of angiogenesis: from microscope to clinic. Nature Med 9, 713—25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McIntosh, M.W., and Urban, N. (2003). A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 4, 27—40.[Abstract]
  • Mendelsohn, J., and Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14), 2787—99.[Abstract/Free Full Text]
  • Mengel, M., von Wasielewski, R., Wiese, B., Rudiger, T., Muller-Hermelink, H., and Kreipe, H. (2002). Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198, 292—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nicholson, J.K., Connelly, J., Lindon, J.C., and Holmes, E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev Drug Discov 1(2), 153—61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nicholson, J.K., and Wilson, I.D. (2003). Opinion: understanding `global' systems biology: metabonomics and the continuum of metabolism. Nature Rev Drug Discov 2(8), 668—76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nielsen, U.B., Cardon, M.H., Sinskey, A.J., MacBeath, G., and Sorger, P.K. (2003). Profiling receptor tyrosine kinase activation by using Ab arrays. Proc Natl Acad Sci USA 100, 9330—5.[Abstract/Free Full Text]
  • Nishizuka, S., Chen, S., Gwadry, F.G., Alexander, J., Major, S.M., Scherf, U., Reinhold, W.C., Waltham, M., Charbonneau, L., Young, L., Bussey, K.J., Kim, S., Lababidi, S., Lee, J.K., Pittaluga, S., Scudiero, D.A., Sausville, E.A., Munson, P.J., Petricoin, E.F., Liotta, L.A., Hewitt, S.M., Raffeld, M., and Weinstein, J.N. (2003). Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic and tissue array profiling. Cancer Res 63, 5243—50.[Abstract/Free Full Text]
  • Ochs, M.F., and Godwin, A.K. (2003). Microarrays in cancer: research and application. Biotechniques 34, S4—S15.
  • Parekattil, S.J., Fisher, H.A., and Kogan, B.A. (2003). Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractatn protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol 169, 917—20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parton, M., Krajewski, S., Smith, I., Krajewska, M., Archer, C., Naito, M., Ahern, R., Reed, J., and Dowsett, M. (2002). Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 8(7), 2100—8.[Abstract/Free Full Text]
  • Paweletz, C.P., Charboneau, L., Bichsel, V.E., Simone, N.L., Chen, T., Gillespie, J.W., Emmert-Buck, M.R., Roth, M.J., Petricoin, E.F., and Liotta, L.A. (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pepe, M.S., Etzioni, R., Feng, Z.D., Potter, J.D., Thompson, M.L., Thornquist, M., Winget, M., and Yasui, Y. (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14), 1054—61.[Free Full Text]
  • Petricoin, E.F., Hackett, J.L., Lesko, L.J., Puri, R.K., Gutman, S.I., Chumakov, K., Woodcock, J., Feigal, D.W., Zoon, K.C., and Sistare, F.D. (2002). Medical applications of microarray technologies: a regulatory science perspective. Nature Genet 32(Suppl. S), 474—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C., and Liotta, L.A. (2002). Clinical proteomics: Translating benchside promise into bedside reality. Nature Rev Drug Discov 1(9), 683—95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ringner, M., and Peterson, C. (2003). Microarray-based cancer diagnosis with artificial neural networks. Biotechniques 34, S30—5.
  • Rolan, P., Atkinson, A.J., and Lesko, L.J. (2003). Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 73, 284—91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ross, B.D., Moffat, B.A., Lawrence, T.S., Mukherji, S.K., Gebarski, S.S., Quint, D.J., Johnson, T.D., Junck, L., Robertson, P.L., Muraszko, K.M., Dong, Q., Meyer, C.R., Bland, P.H., McConville, P., Geng, H., Rehemtulla, A., and Chenevert, T.L. (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2, 581—7.[Abstract/Free Full Text]
  • Rudin, M., and Weissleder, R. (2003). Molecular imaging in drug discovery and development. Nature Rev Drug Discov 2, 123—31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sabri, S., Richelme, F., Pierres, A., Benoliel, A., and Bongrand, P. (1997). Interest of image processing in cell biology and immunology. J Immunol Meth 208, 1—27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sauter, G., Simor, R., and Hillan, K. (2003). Tissue microarrays in drug discovery. Nature Drug Disc 2, 962—72.[CrossRef]
  • Sidransky, D. (2002). Emerging molecular markers of cancer. Nature Rev Cancer 2, 210—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sindhi, R., Allaert, J., Gladding, D., Haaland, P., Koppelman, B., Dunne, J., and Sehgal, S. (2003). Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses—potential clinical implications. J Immunol Meth 272(1—2), 257—72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shockcor, J.P., and Holmes, E. (2002). Metabonomic applications in toxicity screening and disease diagnosis. Curr Top Med Chem 2, 35—51.[CrossRef][Medline] [Order article via Infotrieve]
  • Srinivas, P.R., Verma, M., Zhao, Y.M., and Srivastava, S. (2002). Proteomics for cancer biomarker discovery. Clin Chem 48(8), 1160—9.[Abstract/Free Full Text]
  • Staal, F.J.T., van der Burg, M., Wessels, L.F.A., Barendregt, B.H., Baert, M.R.M., van den Burg, C.M.M., Van Huffel, C., Langerak, A.W., van der Velden, V.H.J., Reinders, M.J.T., and van Dongen, J.J.M. (2003). DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 17(7), 1324—32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stadler, W. (2002). New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs 20, 201—8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sturgeon, C. (2002). Practice guidelines for tumor marker use in the clinic. Clin Chem 48(8), 1151—9.[Abstract/Free Full Text]
  • Swanson, B.N. (2002) Delivery of high-quality biomarker assays. Dis Markers 18(2), 47—56.[Web of Science][Medline] [Order article via Infotrieve]
  • Tarnok, A., and Gerstner, A.O.H. (2003). Clinical applications of laser scanning cytometry. Cytometry 50, 133—43.[CrossRef][Web of Science]
  • Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C., and Gwyther, S.G. (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92, 205—16.[Abstract/Free Full Text]
  • Ugrinska, A., Bombardieri, E., Stokkel, M.P.M., Crippa, F., and Pauwels, E.K.J. (2002). Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med 46(2), 88— 104.[Web of Science][Medline] [Order article via Infotrieve]
  • van der Velden, V.H.J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., and van Dongen, J.J.M. (2003). Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17(6), 1013—34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Veltri, R.W., Miller, M.C., and An, G. (2001). Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 57(4A Suppl. S), 164—70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Welsh, J.B., Sapinoso, L.M., Kern, S.G., Brown, D.A., Liu, T., Bauskin, A.R., Ward, R.L., Hawkins, N.J., Quinn, D.I., Russell, P.J., Sutherland, R.L., Breit, S.N., Moskaluk, C.A., Frierson, H.F., and Hampton, G.M. (2003). Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 100, 3410—5.[Abstract/Free Full Text]
  • Wulfkuhle, J.D., Liotta, L.A., and Petricoin, E.F. (2003). Proteomic applications for the early detection of cancer. Nature Rev Cancer 3(4), 267—75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yamori, T. (2003). Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52 (Suppl. 1), S74—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zehentner, B.K., Dillon, D.C., Jiang, Y.Q., Xu, J.C., Bennington, A., Molesh, D.A., Zhang, X.Q., Reed, S.G., Persing, D.H., and Houghton, R.L. (2002). Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 48(8), 1225—31.[Abstract/Free Full Text]

Toxicologic Pathology, Vol. 32, No. 1 suppl, 106-115 (2004)
DOI: 10.1080/01926230490425021
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
X. Feng, P. Taggart, L. Hall, S. Bryant, J. Sansone, M. Kemmerer, J. Herlich, and P. Lord
Limited Additional Release of Cardiac Troponin I and T in Isoproterenol-Treated Beagle Dogs with Cardiac Injury
Clin. Chem., July 1, 2005; 51(7): 1305 - 1307.
[Full Text] [PDF]

Home page
 aacredbookHome page
B. Fingleton
Learning from Our Mistakes: The Translation of MMPIs from Laboratory to Clinical Trial
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 30 - 32.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Floyd, E.
Right arrow Articles by Mcshane, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Floyd, E.
Right arrow Articles by Mcshane, T. M.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cancer
*Cancer Chemotherapy
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?